Inhibitors of Hsp90 (Hsp90-I) effect numerous proteins and pathways that are critical to the etiology of prostate cancer [2-4] and have demonstrated significant anti-proliferative effects in multiple cancer models, many of which are being evaluated in clinical trials [5]. The gene discussed is HSP90AA1; the disease is cancer.